JP2019537596A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537596A5
JP2019537596A5 JP2019523672A JP2019523672A JP2019537596A5 JP 2019537596 A5 JP2019537596 A5 JP 2019537596A5 JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019537596 A5 JP2019537596 A5 JP 2019537596A5
Authority
JP
Japan
Prior art keywords
theta
hexafluoropropan
trifluoromethyl
benzyl
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537596A (ja
JP7042548B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061875 external-priority patent/WO2018093953A1/en
Publication of JP2019537596A publication Critical patent/JP2019537596A/ja
Publication of JP2019537596A5 publication Critical patent/JP2019537596A5/ja
Priority to JP2022035398A priority Critical patent/JP7350117B2/ja
Application granted granted Critical
Publication of JP7042548B2 publication Critical patent/JP7042548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523672A 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態 Expired - Fee Related JP7042548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035398A JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035398A Division JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2019537596A JP2019537596A (ja) 2019-12-26
JP2019537596A5 true JP2019537596A5 (enExample) 2020-12-24
JP7042548B2 JP7042548B2 (ja) 2022-03-28

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523672A Expired - Fee Related JP7042548B2 (ja) 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Country Status (38)

Country Link
US (2) US11142517B2 (enExample)
EP (2) EP3541807B1 (enExample)
JP (2) JP7042548B2 (enExample)
KR (1) KR102508739B1 (enExample)
CN (2) CN110291083B (enExample)
AU (1) AU2017361257B2 (enExample)
BR (1) BR112019010003A2 (enExample)
CA (1) CA3043610A1 (enExample)
CL (1) CL2019001340A1 (enExample)
CO (1) CO2019005045A2 (enExample)
CR (1) CR20190242A (enExample)
CY (1) CY1124870T1 (enExample)
DK (1) DK3541807T3 (enExample)
DO (1) DOP2019000120A (enExample)
EA (1) EA201991086A1 (enExample)
EC (1) ECSP19035171A (enExample)
ES (2) ES2900016T3 (enExample)
GE (1) GEP20237559B (enExample)
HR (2) HRP20231697T1 (enExample)
HU (2) HUE064559T2 (enExample)
IL (1) IL266548A (enExample)
JO (1) JOP20190109B1 (enExample)
LT (1) LT3541807T (enExample)
MA (2) MA58133B1 (enExample)
MX (2) MX389459B (enExample)
MY (1) MY199386A (enExample)
NI (1) NI201900053A (enExample)
PE (1) PE20191239A1 (enExample)
PH (1) PH12019501068A1 (enExample)
PL (2) PL3964503T3 (enExample)
PT (1) PT3541807T (enExample)
RS (2) RS65016B1 (enExample)
SI (1) SI3541807T1 (enExample)
SM (2) SMT202300494T1 (enExample)
TN (1) TN2019000151A1 (enExample)
UA (1) UA124585C2 (enExample)
WO (1) WO2018093953A1 (enExample)
ZA (1) ZA201903093B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
RS64006B1 (sr) 2017-05-23 2023-03-31 H Lundbeck As Pirazol magl inhibitori
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
KR20210033504A (ko) * 2018-07-19 2021-03-26 화이자 인코포레이티드 Magl 억제제로서 헤테로환형 스피로 화합물
HUE067912T2 (hu) 2018-08-13 2024-11-28 Hoffmann La Roche Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok
WO2020154683A1 (en) * 2019-01-25 2020-07-30 Lundbeck La Jolla Research Center, Inc. Methods of treating disease with magl inhibitors
CN114761382A (zh) * 2019-11-15 2022-07-15 H.隆德贝克有限公司 Magl抑制剂的晶型
KR20230004622A (ko) * 2020-04-21 2023-01-06 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제의 합성
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
DE69231313T2 (de) 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
HUP0302455A3 (en) 2000-12-18 2005-05-30 Novartis Ag Combination pharmaceutical compositions containing amplodipine and benazepril and their use
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1478363B1 (en) 2002-02-20 2009-01-14 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
NZ627750A (en) * 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
SMT202500078T1 (it) 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
EP3134092B1 (en) 2014-04-21 2020-06-24 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
MX2017014344A (es) * 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Similar Documents

Publication Publication Date Title
JP2019537596A5 (enExample)
JP2022084717A5 (enExample)
JP2017527578A5 (enExample)
HRP20231697T1 (hr) Kristalni oblik magl inhibitora
JOP20190182A1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
JP2015517981A5 (enExample)
EP4467143A3 (en) 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
HRP20170634T4 (hr) Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
JP2012509263A5 (enExample)
JP2018511587A5 (enExample)
JP2016503786A5 (enExample)
JP2012507535A5 (enExample)
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
NZ627750A (en) Carbamate compounds and of making and using same
JP2017526711A5 (enExample)
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
JP2018507877A5 (enExample)
JP2017534569A5 (enExample)
JP2009502795A5 (enExample)
NZ617334A (en) Cyclopropyl amine derivatives
JP2013510876A5 (enExample)
JP2012512885A5 (enExample)
JP2018168191A5 (enExample)
WO2010133976A3 (en) Substantially pure imatinib or a pharmaceutically acceptable salt thereof